Allos Therapeutics (ALTH) Tops Q4 EPS by 6c

Allos Therapeutics (NASDAQ: ALTH) reported Q4 EPS of ($0.01), $0.06 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.94 million.

For earnings history and earnings-related data on Allos Therapeutics (ALTH) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c